Kim P. Kamdar

Kim joined Domain in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Kim has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Kim's present board memberships include Ariosa Diagnostics, Epic Sciences, Neothetics, Obalon Therapeutics, ROX Medical, Sera Prognostics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. Kim was also involved with Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to sanofi-aventis in April 2009. Prior to Domain, Kim was a Kauffman Fellow with MPM Capital. Prior to joining MPM, Kim was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Kim is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. Kim serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and of Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. Kim is also a board member of San Diego's CONNECT Foundation and the Hastings Center, a nonpartisan bioethics research institution.